SPARC signs license agreement with Tripoint Therapeutics for Elepsia XR tablets
SPARC will be eligible to receive tiered royalties ranging from 15 per cent to 50 per cent on net sales
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Elepsia XR
US FDA reverses NDA nod for Sun Pharma’s anti epileptic drug
SPARC had earlier received a final approval from US FDA in March 2015 for this product Sun Pharma Advanced Research Company…